Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have been given a consensus rating of “Hold” by the eight research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $37.33.
Several equities research analysts have recently issued reports on URGN shares. BidaskClub upgraded shares of UroGen Pharma from a “strong sell” rating to a “sell” rating in a research report on Thursday. ValuEngine lowered shares of UroGen Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 26th. JPMorgan Chase & Co. cut their target price on shares of UroGen Pharma from $31.00 to $26.00 in a report on Monday, September 21st. Finally, Oppenheimer cut their target price on shares of UroGen Pharma from $48.00 to $40.00 in a report on Tuesday, November 10th.
In other news, CEO Elizabeth A. Barrett acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 14th. The stock was purchased at an average cost of $18.50 per share, for a total transaction of $185,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 229,117 shares of the company’s stock, valued at approximately $4,238,664.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Peter P. Pfreundschuh sold 2,400 shares of UroGen Pharma stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $21.77, for a total value of $52,248.00. Following the completion of the sale, the chief financial officer now owns 12,805 shares of the company’s stock, valued at $278,764.85. The disclosure for this sale can be found here. Insiders have sold 3,163 shares of company stock valued at $67,505 over the last ninety days. 12.00% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its holdings in UroGen Pharma by 1.4% in the third quarter. BlackRock Inc. now owns 1,485,601 shares of the company’s stock worth $28,657,000 after purchasing an additional 19,796 shares in the last quarter. Phoenix Holdings Ltd. grew its stake in shares of UroGen Pharma by 0.5% during the third quarter. Phoenix Holdings Ltd. now owns 901,979 shares of the company’s stock worth $16,405,000 after acquiring an additional 4,515 shares during the last quarter. FMR LLC grew its stake in shares of UroGen Pharma by 5.8% during the first quarter. FMR LLC now owns 588,203 shares of the company’s stock worth $21,728,000 after acquiring an additional 32,200 shares during the last quarter. Nuveen Asset Management LLC grew its stake in shares of UroGen Pharma by 24.5% during the second quarter. Nuveen Asset Management LLC now owns 337,149 shares of the company’s stock worth $8,807,000 after acquiring an additional 66,316 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of UroGen Pharma by 19.8% during the second quarter. Goldman Sachs Group Inc. now owns 143,265 shares of the company’s stock worth $3,742,000 after acquiring an additional 23,728 shares during the last quarter. Institutional investors and hedge funds own 69.95% of the company’s stock.
UroGen Pharma stock opened at $21.00 on Friday. The stock has a market cap of $438.84 million, a P/E ratio of -3.41 and a beta of 1.69. UroGen Pharma has a 1 year low of $13.12 and a 1 year high of $35.00. The firm’s 50 day moving average price is $19.27 and its 200-day moving average price is $21.95.
UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, November 9th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.16. The company had revenue of $3.46 million for the quarter, compared to the consensus estimate of $3.21 million. Sell-side analysts expect that UroGen Pharma will post -6.14 earnings per share for the current fiscal year.
UroGen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company’s lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.
Featured Story: What is the Coverage Ratio?
Receive News & Ratings for UroGen Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for UroGen Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.